From: Relevance of tumor-infiltrating lymphocytes in breast cancer
Drug | Target | Immunological effects and model used | Reference |
---|---|---|---|
Gemcitabine | Nucleoside analogue, prevents DNA replication | Reduction in the number of MDSCs | [126] |
HER2/neu model; breast cancer | |||
Mesothelioma and lung cancer models | [48] | ||
Reduction in MDSCs and Tregs when given with cyclophosphamide; CT26 colon carcinoma | [49] | ||
Reduction of Tregs in patients with pancreatic cancer | |||
Cyclophosphamide | DNA alkylation, cross-links DNA | Induction of immunogenic cell death, IFN-I mediated activation of dendritic cells; EG7 thymoma, B16F10 melanoma | [129] |
Selective depletion of Tregs in MMTV-neu mice (breast cancer) | [88] | ||
Selective depletion of Tregs in colon carcinoma model | [42] | ||
Selective depletion of Tregs in melanoma model | [130] | ||
Reduction in MDSCs and Tregs when given with gemcitabine; CT26 colon carcinoma | [48] | ||
Paclitaxel | Inhibition of mitosis through tubulin targeting | Reduction in MDSC frequency and suppressive activity | [131] |
Reduction in Treg numbers and suppressive activity | |||
Anthracyclines | Multiple mechanisms | Induction of immunogenic cell death; thymoma model, CT26 colon carcinoma | [45] |
Differentiation of CD11b+ LY6C+ APCs; MCA205 fibrosarcoma | [133] | ||
Elimination of MDSCs; 4 T1 and EMT6 breast tumor cell lines | [134] | ||
Oxaliplatin | Cross-links DNA | Induction of immunogenic cell death resulting in the activation of myeloid cells; thymoma/colon cancer model | |
Cisplatin | Cross-links DNA | Induce the accumulation of CD11c+ inflammatory dendritic cells; lung/colon carcinoma models | [136] |
Docetaxel | Inhibition of mitosis through tubulin targeting | Reduction in MDSC frequency and suppressive activity; B16 melanoma model | [116] |
5-aza-2′-deoxycytidine | DNA methyltransferase inhibition | Increased antigen presentation by tumor cells; 4 T1 breast cancer model | [137] |
Reduction in MDSCs and suppressive function; lung/prostrate carcinoma | [138] |